SCHEMBL30679687

SCHEMBL30679687

CCOC(=O)NC(=S)Nc1ncc(Br)cc1C(=O)NC(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ NPC1 O15118 3/20 0.42
▸ KCNH2 Q12809 2/20 0.42
▸ RAB9A P51151 2/20 0.41
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ GAA P10253 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ MAPK14 Q16539 1/20 0.37
▸ OPRK1 P41145 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26857507 1.00 MAPT (0.45) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL22585510 0.93 MAPT (0.43) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL22585498 0.93 MAPT (0.43) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL30248509 0.93 MAPT (0.43) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL30248563 0.92 MAPT (0.42) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL22585735 0.92 MAPT (0.42) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL29114895 0.92 MAPT (0.42) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL30248581 0.91 MAPT (0.41) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL22585489 0.91 MAPT (0.41) MAPTLMNAPKMSMN1; SMN2NPC1
SCHEMBL22585577 0.90 MAPT (0.41) MAPTLMNAPKMSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612399-B2 Substituted 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide derivatives and use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2026-04-28 — — US disclosed
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612399-B2 Substituted 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide derivatives and use thereof SNCA, CBR1, CBR3 MAPT 449/4885LMNA 757/4885PKM 3957/4885
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF SNCA, PSEN2, PARK7 MAPT 13/4885LMNA 2005/4885PKM 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback